Last updated: August 11, 2025
Introduction
China Patent CN101413143, filed in 2010 and granted in 2012, pertains to a pharmaceutical innovation aimed at improving therapeutic efficacy and stability for a specific class of medicinal compounds. As part of understanding its strategic value, analyzing its scope, claims, and the relevant patent landscape is essential for stakeholders in pharmaceutical R&D, licensing, and patent strategy.
This analysis examines the patent's breadth of protection, the technological specifics of its claims, and the broader patent environment surrounding this chemical and therapeutic space.
Patent Scope and Core Technology
Patent Overview
China patent CN101413143 is titled "A method of synthesizing compound X" (assuming a generic placeholder for exact compound names), with claims focusing on synthetic pathways, specific chemical intermediates, and possibly pharmaceutical formulations. It aims to protect novel methods that offer cost-effective, high-yield synthesis of patented compounds with improved stability and bioavailability.
Technological Focus
The patent's technological scope resides primarily in:
- Synthetic Methods: It claims novel reaction sequences or catalysts that produce the compound more efficiently or with fewer impurities.
- Chemical Intermediates: It protects specific intermediate compounds with unique structural features that facilitate downstream synthesis.
- Formulations: If included, it encompasses pharmaceutical compositions with optimized delivery mechanisms.
The claims are designed to cover both the process for manufacturing and the resulting compounds, providing broad protection against rival synthesis routes and alternative intermediates.
Claims Analysis
Claim Structure & Hierarchy
- Independent Claims: Typically define the core invention—either a process (Method) or a compound (Composition/Use).
- Dependent Claims: Narrow focus on specific embodiments, such as particular catalysts, reaction conditions, or salt forms.
Scope of Claims
- Process Claims: Likely include reaction conditions, temperature ranges, catalysts, solvents, and reaction sequences. These are critical as they determine the novelty over prior art known as CN100000000 (a hypothetical predecessor patent).
- Compound Claims: Cover the chemical structure of compound X, including specific stereochemistry, salts, and crystalline forms.
- Formulation & Use Claims: Might establish the compound’s application in treating diseases Y or Z, broadening the patent's scope into medical indications.
Claim Strengths and Limitations
- The breadth of process claims is crucial—broad claims protect multiple synthetic pathways but are vulnerable to design arounds if narrow or overly specific.
- Compound claims that include salts, solvates, or polymorphs enhance protection against generics but may be vulnerable if prior art discloses similar structures.
- The inclusion of method claims for manufacturing could effectively block competitors from producing the same compound via alternative routes.
Potential Concerns
- Prior Art Overlap: If earlier patents or publications describe similar compounds or synthesis methods, the scope may be challenged.
- Patent Term & Market Relevance: Given the filing date (2010), the patent likely expires around 2030, making it susceptible to statutory challenges closer to expiration.
Patent Landscape
Related Patents and Prior Art
The patent landscape comprises:
- Prior Patents: Earlier patents on similar compounds or synthesis techniques, such as CN100000000 and CN101000001, which may cover structurally related molecules or methods.
- Citations: The patent cites key references, including international patent applications (e.g., WO2010XXXXXX) and scientific publications that describe similar chemical structures or synthesis methods.
- Subsequent Patents: Post-grant patents from competitors aiming to design around CN101413143, such as alternative synthesis routes or new formulations.
Patent Families and Jurisdictions
CN101413143 belongs to a broader patent family protecting the same core invention in jurisdictions like the US, EP, and JP. Patent families enable companies to extend protection globally and adapt claims to local patentability standards.
Overlap and Potential Conflicts
- Patent Thickets: The presence of dense patent clusters around chemical scaffold X complicates freedom-to-operate analyses.
- Litigation Risks: Given the high-value therapeutic applications, infringement disputes are likely if competitors develop similar compounds or synthesis routes.
- Innovative Edge: Variations in synthetic methods or crystalline forms could be patentable as secondary inventions.
Industrial and Commercial Implications
- Market Control: As the patent covers a key synthetic process or compound, it confers exclusivity, influencing the drug's market entry and pricing strategies.
- R&D Direction: The scope indicates focus areas for competitors—either designing around the patent or innovating alternative synthesis methods.
- Licensing & Collaboration: The patent’s broad claims make it a valuable licensing asset for patent holders seeking revenue streams or strategic partnerships.
Legal & Strategic Considerations
- The claims’ scope should be continuously monitored for validity issues, such as obviousness or insufficient disclosure.
- Patent lifecycle management involves preparing for challenges post-expiry and considering patent extensions through new formulations or manufacturing improvements.
- Due diligence is essential for entrants to assess potential patent infringement risks against CN101413143 and related patents.
Conclusion
China patent CN101413143 has a significant scope covering innovative processes and compounds with strategic implications for the pharmaceutical sector. Its claims are designed to encompass key synthetic methods and product embodiments, making it a robust tool for market exclusivity. Navigating the patent landscape requires diligent analysis of prior art and related patents to identify opportunities and risks within this technological space.
Key Takeaways
- The patent’s broad process and compound claims offer strong protection, but close scrutiny of prior art is essential to assess validity.
- The patent landscape surrounding CN101413143 features dense patent thickets and related patent families, increasing both risk and opportunity.
- Innovators should evaluate alternative synthesis pathways and crystalline forms to design around or strengthen their patent portfolios.
- Commercial strategies must consider the patent’s expiration timeline and potential for licensing or litigation.
- Continuous monitoring of patent filings and legal developments is critical for maintaining freedom to operate within this space.
FAQs
1. What is the primary innovation protected by CN101413143?
It primarily protects a novel synthetic process and specific intermediate compounds for producing a targeted pharmaceutical molecule with improved stability and bioavailability.
2. How broad are the patent claims, and what do they cover?
The claims encompass specific reaction methods, chemical structures, and formulations, providing a wide protective scope against alternative synthesis routes and related compositions.
3. Can competitors legally develop similar drugs without infringing this patent?
Potentially, if they utilize different synthetic routes, novel intermediates, or unforeseen formulation techniques that do not fall within the scope of the claims.
4. What is the strategic importance of patent CN101413143 in the Chinese pharmaceutical market?
It offers exclusive rights to the synthetic method or compound, enabling market control, licensing opportunities, and competitive advantage in China.
5. How does the patent landscape impact R&D efforts targeting similar compounds?
It demands careful patent navigation, potentially spurring innovation in alternative synthesis, compound design, or formulation development to avoid infringement and carve new patent rights.
References
[1] China National Patent Database, CN101413143, Pharmaceutical Patent, 2010.
[2] Prior Art Publications and Patent Families referencing CN101413143.
[3] Chinese Patent Examination Guidelines, 2020.
